Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Celsion Corp (CLSN)

Celsion Corp (CLSN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Help
Go To:
Celsion Corporation to Hold Second Quarter 2022 Financial Results and Business Update Conference Call on Monday, August 15, 2022 Globe Newswire - Mon Aug 8, 2022

LAWRENCEVILLE, N.J., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based...

CLSN : 1.9600 (unch)
Celsion Corporation Reports Inducement Grants under NASDQ Listing Rule 5646(c)(4) Globe Newswire - Tue Jul 19, 2022

LAWRENCEVILLE, N.J., July 19, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy...

CLSN : 1.9600 (unch)
Celsion Reports Data Safety Monitoring Board Unanimous Recommendation to Continue Dosing Patients in the Phase II Portion of the OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer Globe Newswire - Tue Jun 21, 2022

Novel Gene-Mediated Immunotherapy is Safe and Demonstrates an Acceptable Risk/Benefit Full Enrollment Expected by Third Quarter of 2022 ...

CLSN : 1.9600 (unch)
Advanced Clinical Trials Focus on Development of Vaccines to Prevent Ovarian Cancer Progression FinancialNewsMedia - Wed May 18, 2022

Palm Beach, FL – May 18, 2022 – FinancialNewsMedia.com News Commentary – Companies in the Ovarian Cancer market are spending a lot of R&D on vaccine development, therapies and studies. For the past...

BIOV.CN : 0.0650 (unch)
BVAXF : 0.0461 (-5.73%)
CLSN : 1.9600 (unch)
IMGN : 31.23 (unch)
ZNTL : 3.22 (+1.26%)
BMY : 57.76 (+0.31%)
Celsion Corporation Highlights Pipeline Progress in Its Lead Development Candidates Globe Newswire - Tue May 10, 2022

PLACCINE DNA-based Vaccine in proof-of-concept non-Human Primate Studies Phase II study of GEN-1 in ovarian cancer 85% enrolled with full enrollment...

CLSN : 1.9600 (unch)
Celsion Corporation to Hold First Quarter 2022 Financial Results and Business Update Conference Call on Monday, May 16, 2022 Globe Newswire - Mon May 9, 2022

LAWRENCEVILLE, N.J., May 09, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based...

CLSN : 1.9600 (unch)
Celsion Corporation Highlighted its PLACCINE Vaccine Platform Technology During Oral Presentation at the World Vaccine Congress Globe Newswire - Thu Apr 21, 2022

Proprietary, Formulated DNA Plasmid Vaccine Candidate Shows Neutralizing Activity Against 2 Strains of the COVID-19 Virus The Goal to Provide...

CLSN : 1.9600 (unch)
Celsion and Medidata Present Findings on Use of Synthetic Control Arm to Estimate Treatment Effect in Ovarian Cancer Trial at 2022 AACR Annual Meeting Globe Newswire - Thu Apr 14, 2022

 Phase Ib dose-escalating OVATION I Study with GEN-1 in advanced ovarian cancer patients was well received at 2022 AACR Annual Meeting LAWRENCEVILLE,...

CLSN : 1.9600 (unch)
Celsion Corporation to Highlight its PLACCINE Platform Technology During Oral Presentation at the World Vaccine Congress Globe Newswire - Tue Apr 12, 2022

LAWRENCEVILLE, N.J., April 12, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), a clinical-stage company focused on DNA-based immunotherapy...

CLSN : 1.9600 (unch)
Celsion Corporation Announces Closing of $7.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules Globe Newswire - Fri Apr 8, 2022

LAWRENCEVILLE, NJ, April 08, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) (“Celsion” or the “Company”), today announced the closing of its...

CLSN : 1.9600 (unch)

Barchart Exclusives

Truist Analysts Love This Dividend Stock With a 15% Yield Barchart - Tue Dec 24, 6:30PM CST
Truist analysts are bullish on Mach Natural Resources (MNR), a new energy stock offering a 15% dividend yield and 45.5% upside potential. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot